PathMaker's MyoRegulator Device for ALS Receives IRB Approval for DoD-Funded Clinical Trial
• PathMaker Neurosystems has received IRB approval to begin enrollments in the CALM study, a clinical trial of the MyoRegulator device for ALS.
• The CALM study, funded by the U.S. Department of Defense, will assess the safety and feasibility of MyoRegulator in ALS patients.
• MyoRegulator uses multi-site direct current stimulation to modulate neurons and circuits associated with ALS, suppressing motor neuron hyperexcitability.
• The trial will be conducted at Beth Israel Deaconess Medical Center, led by neurology experts from Harvard Medical School.
© Copyright 2025. All Rights Reserved by MedPath